The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
Open accessAbstract
Introduction: The aim of the current study was to investigate whether consolidative local ablative therapy (LAT) can improve the survival of patients with stage IV EGFR‐mutant NSCLC who have oligometastatic disease treated with first‐line EGFR–tyrosine kinase inhibitor (TKI) therapy. Methods: Patients with stage IV EGFR‐mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified. All patients were treated with first‐line EGFR‐TKIs. Consolidative LAT included radiotherapy, surgery, or both. Overall survival (OS) and progression‐free survival (PFS) were estimated by Kaplan‐Meier curves. Results: From October 2010 to May 2016, 145 patients were enrolled, including 51 (35.2%) who received consolidative LAT to all oligometastatic sites (all‐LAT group), 55 (37.9%) who received consolidative LAT to either primary tumor or oligometastatic sites (part‐LAT group), and 39 (26.9%) who did not receive any consolidative LAT (non‐LAT group). The median PFS in all‐LAT, part‐LAT, and non‐LAT groups were 20.6, 15.6, and 13.9 months, respectively (p < 0.001). The median OS in all‐LAT, part‐LAT, and non‐LAT groups were 40.9, 34.1, and 30.8 months, respectively (p < 0.001). The difference was statistically significant between the all‐LAT group and part‐LAT or non‐LAT group but was not between the part‐LAT and non‐LAT group. The median OS was significantly improved with consolidative LAT for primary tumor (40.5 versus 31.5 months, p < 0.001), brain metastases (38.2 versus 29.2 months, p = 0.002), and adrenal metastases (37.1 versus 29.2 months, p = 0.032). Adverse events (grade ≥ 3) due to radiotherapy included pneumonitis (7.7%) and esophagitis (16.9%). Conclusions: The current study showed that consolidative LAT to all metastatic sites was a feasible option for patients with EGFR‐mutant oligometastatic NSCLC during first‐line EGFR‐TKI treatment, with significantly improved PFS and OS compared with consolidative LAT to partial sites or observation alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Self-citationGomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30532-0 · Cited by 1,086
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684
De Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A.-M. C., Reymen, B., Houben, R., Bootsma, G., Pitz, C., van Eijsden, L., Geraedts, W., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318262caf6 · Cited by 283
Cited by
Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00201 · Cited by 1,283
Wang, X.-S., Bai, Y.-F., Verma, V., Yu, R.-L., Tian, W., Ao, R., Deng, Y., Zhu, X.-Q., Liu, H., Pan, H.-X., et al. (2023) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djac015 · Cited by 272
Self-citation
Metadata
- Authors
- Xu, Q., Zhou, F., Liu, H., Jiang, T., Li, X., Xu, Y., & Zhou, C.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 13
- Issue
- 9
- Pages
- 1383-1392
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2806810471
- Cited by
- 192
- References
- 7
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. https://app.cochat.ai/papers/10.1016/j.jtho.2018.05.019
- The paper
- Xu, Q., Zhou, F., Liu, H., Jiang, T., Li, X., Xu, Y., & Zhou, C. (2018). Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.05.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.